Corporate Profile

At Talis, we strive to deliver excellence in point of care diagnostics by increasing access to timely and accurate testing that can help combat the spread of known and emerging infectious diseases.

Stock Information

Data Provided by Refinitiv. Minimum 15 minutes delayed.

Press Releases

18 Mar '21
MENLO PARK, Calif., March 18, 2021 (GLOBE NEWSWIRE) -- Talis Biomedical Corporation (Nasdaq: TLIS), a company dedicated to developing innovative molecular diagnostic tests for infectious diseases at the point-of-care, today announced the appointment of Jeryl “Jeri” Hilleman to its Board of

Recent Events